### Analysis:

Merck's Q1 2019 earnings call highlighted strong quarterly performance, driven primarily by the oncology segment, particularly KEYTRUDA. The company reported robust sales growth, with KEYTRUDA achieving significant milestones in various markets, including China and Europe. The outlook for 2019 is cautiously optimistic, with guidance for revenue growth and EPS expansion. Management emphasized the potential of their pipeline, including the pneumococcal vaccine V114, and the continued success of their innovative products. The company also discussed their strategy to pivot towards more innovative products, which is expected to drive long-term growth.

### Conclusion:

The short-term (1-2 weeks) impact on Merck's stock price is likely to be positive, driven by the strong Q1 results and optimistic guidance. The company's focus on innovation and the potential of their pipeline suggest sustained growth prospects. However, investors should closely monitor the regulatory environment and any potential competitive threats, especially in the Chinese market. The stock is expected to rally in the short term, driven by the positive earnings report and the company's strategic focus on innovation.

**Rating: 2**